AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER

Trial Profile

AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 19 May 2016 Time frame of primary endpoint changed from 3.5 years to 4 years.
    • 01 Oct 2015 Planned End Date changed from 1 Oct 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top